On February 23, 2015 Prescient Therapeutics (ASX: PTX), a clinical stage oncology company, announced today that the U.S Patent and Trademark Office has granted two additional patents that underpin the development and commercialisation of its drug candidate PTX-200. U.S. patent 8,906,869, provides broad protection for the company’s novel method of treating chemotherapy resistant ovarian cancer with the AKT inhibitorcompound PTX-200, formerly known as TCN-P or triciribine phosphate monohydrate (Press release, Prescient Therapeutics, FEB 23, 2015, View Source [SID1234517542]). The second U.S. patent 8,901,086, provides broad coverage for treating various cancer types including breast cancer by administering PTX-200 in combination with trastuzumab.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Robert Crombie, Managing Director of Prescient Therapeutics, said, "These U.S. patents further enhance our intellectual property portfolio. They confirm our monopoly rights on this novel and highly encouraging compound which we believe has significant potential to improve the clinical outcome for women with chemotherapy-resistant ovarian cancer."
"Prescient’s drug candidate PTX-200 is being trialed in patients who have become resistant to platinum-based drugs as it inhibits the AKT tumor survival pathway associated with platinum drug resistance PTX-200, in combination with standard of care drug carboplatin, is currently in Phase 1b/2 trial as a new therapy for ovarian cancer, the fifth leading cause of cancer death in women in the United States. Currently approximately half of the patients diagnosed with ovarian cancer will die from metastatic disease as they become resistant to the platinum-based drugs that constitute front line therapy. Prescient’s drug candidate PTX-200 is aiming to minimise this resistance."